RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

被引：0
|
作者：
Adrián Sanz-Moreno
Sonia Palomeras
Kim Pedersen
Beatriz Morancho
Tomas Pascual
Patricia Galván
Sandra Benítez
Jorge Gomez-Miragaya
Marina Ciscar
Maria Jimenez
Sonia Pernas
Anna Petit
María Teresa Soler-Monsó
Gemma Viñas
Mansour Alsaleem
Emad A. Rakha
Andrew R. Green
Patricia G. Santamaria
Celine Mulder
Simone Lemeer
Joaquin Arribas
Aleix Prat
Teresa Puig
Eva Gonzalez-Suarez
机构：
[1] Oncobell,Present Address: German Mouse Clinic
[2] Bellvitge Biomedical Research Institute (IDIBELL),New Therapeutics Targets Lab (TargetsLab), Department of Medical Sciences
[3] L’Hospitalet de Llobregat,Preclinical Research Program
[4] Institute of Experimental Genetics,Department of Medical Oncology
[5] HMGU,Present Address: Department of Biomedicine, Department of Surgery
[6] University of Girona,Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO)
[7] Vall d’Hebron Institute of Oncology (VHIO),Pathology Department
[8] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),Medical Oncology Department
[9] Translational Genomics and Targeted Therapeutics in Solid Tumors,Division of Cancer and Stem Cells, School of Medicine
[10] August Pi i Sunyer Biomedical Research Institute (IDIBAPS),Biomolecular Mass Spectrometry and Proteomics Bijvoet Center
[11] SOLTI Breast Cancer Research Group,Medicine Department
[12] Hospital Clinic,undefined
[13] University Hospital Basel,undefined
[14] University of Basel,undefined
[15] Molecular Oncology,undefined
[16] Spanish National Cancer Research Centre (CNIO),undefined
[17] University Hospital of Bellvitge IDIBELL,undefined
[18] L’Hospitalet de Llobregat,undefined
[19] University Hospital of Bellvitge,undefined
[20] IDIBELL,undefined
[21] Catalan Institute of Oncology (ICO),undefined
[22] University of Nottingham Biodiscovery Institute,undefined
[23] Utrecht University,undefined
[24] University of Barcelona,undefined
来源：
Breast Cancer Research | / 23卷
关键词：
Breast cancer; HER2; Lapatinib; NF-κB; RANK; RANKL; Resistance; Trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
    Qian Zhang
    Jian Chen
    Xiaoli Yu
    Gang Cai
    Zhaozhi Yang
    Lu Cao
    Chaosu Hu
    Xiaomao Guo
    Jing Sun
    Jiayi Chen
    [J]. Breast Cancer, 2016, 23 : 732 - 739
  • [32] Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
    Huang, Le-Tian
    Ma, Jie-Tao
    Zhang, Shu-Ling
    Li, Xiao-Han
    Sun, Li
    Jing, Wei
    Zhao, Jian-Zhu
    Wang, Yan-Ru
    Han, Cheng-Bo
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [33] Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer
    Olson, E. M.
    Lin, N. U.
    DiPiro, P. J.
    Najita, J.
    Krop, I. E.
    Winer, E. P.
    Burstein, H. J.
    [J]. CANCER RESEARCH, 2010, 70
  • [34] Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
    Zhang, Qian
    Chen, Jian
    Yu, Xiaoli
    Cai, Gang
    Yang, Zhaozhi
    Cao, Lu
    Hu, Chaosu
    Guo, Xiaomao
    Sun, Jing
    Chen, Jiayi
    [J]. BREAST CANCER, 2016, 23 (05) : 732 - 739
  • [35] Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
    Nahleh, Zeina A.
    Elimimian, Elizabeth B.
    Elson, Leah C.
    Hobbs, Brian
    Wei, Wei
    Blake, Cassann N.
    [J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14
  • [36] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Nguy, Susanna
    Wu, S. Peter
    Oh, Cheongeun
    Gerber, Naamit K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 815 - 830
  • [37] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Susanna Nguy
    S. Peter Wu
    Cheongeun Oh
    Naamit K. Gerber
    [J]. Breast Cancer Research and Treatment, 2021, 187 : 815 - 830
  • [38] Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
    Bradbury, Michelle
    Savard, Marie-France
    Vandermeer, Lisa
    Clemons, Lucas
    Pond, Gregory
    Hilton, John
    Clemons, Mark
    Mcgee, Sharon
    [J]. CURRENT ONCOLOGY, 2023, 30 (12) : 10477 - 10487
  • [39] Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
    Lambertini, Matteo
    Ceppi, Marcello
    Anderson, Richard A.
    Cameron, David A.
    Bruzzone, Marco
    Franzoi, Maria Alice
    Massarotti, Claudia
    El-Abed, Sarra
    Wang, Yingbo
    Lecocq, Christophe
    Nuciforo, Paolo
    Rolyance, Rebecca
    Pusztai, Lajos
    Sohn, Joohyuk
    Latocca, Maria Maddalena
    Arecco, Luca
    Pistilli, Barbara
    Ruddy, Kathryn J.
    Ballestrero, Alberto
    Del Mastro, Lucia
    Peccatori, Fedro A.
    Partridge, Ann H.
    Saura, Cristina
    Untch, Michael
    Piccart, Martine
    Di Cosimo, Serena
    de Azambuja, Evandro
    Demeestere, Isabelle
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 33 - +
  • [40] Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey
    Bradbury, M.
    Savard, Mf
    Stober, C.
    Clemons, L.
    Clemons, M.
    Hilton, J.
    Pond, G.
    Vandermeer, L.
    Mcgee, Sf
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 473 - 481
12345